Treatment of Helicobacter pylori infection in Iran: Low efficacy of recommended western regimens

Archives of Iranian Medicine

Volumn 7, Issue 1, 2004, Pages 1-8

  Malekzadeh, Reza ^a   Mohamadnejad, Mehdi ^a,b   Siavoshi, Farideh ^c   Massarrat, Sadegh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Antibiotics; Eradication; Helicobacter pylori; Iran; Quadruple therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG COST; DRUG EFFICACY; ERADICATION THERAPY; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; IRAN; MEDICAL DOCUMENTATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PEPTIC ULCER; PRACTICE GUIDELINE; REINFECTION; REVIEW; SIDE EFFECT; UREA BREATH TEST; WESTERN HEMISPHERE;

EID: 3042655403     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002; 16 (Suppl 1): 3 - 15.
2. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995; 7: 427 - 33.
3. Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the North-West of Iran. J Clin Pathol. 2004; 57: 37 - 42.
4. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167 - 80.
5. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994; 272: 65 - 9.
6. Siavoshi F, Pourkhajeh AH, Merat S, Asl-Soleimani H, Heydarian E, Khatibian M, et al. Susceptibility of various strains of Helicobacter pylori to selected agents. Arch Iranian Med. 2000; 3: 60 - 3.
7. Massarrat S. Georg Ernst Konjetzny, german surgeon of the 20th century: a great pioneer who suggested the bacterial genesis of gastritis and its relationship to peptic ulcer and gastric cancer. Am J Gastroenterol. 2003. 98: 1899 - 900.
8. Marshall BJ. History of the discovery of C. pylori. In: Blaser MJ, ed. Campylobacter pylori in Gastritis and Peptic Ulcer Disease. New York: Igaku-Shoin; 1989: 7.
9. Rigas B, Feretis C, Papavassiliou ED. John Lykoudis: an unappreciated discoverer of the cause and treatment of peptic ulcer disease. Lancet. 1999; 354: 1634 - 5.
10. Iranian Medical Counsel News [in Persian]. 1986; 5: 8 - 9.
11. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1: 1311 - 5.
12. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Camplylobacter pylori. Lancet. 1988; 2: 1437 - 42.
13. Massarat S. Eradicatin of Campylobacter pylori as a treatment for duodenal ulcer disease. Nabaz J. 1992; 1: 34 - 40.
14. Goh KL. Update on the management of Helicobacter pylori infection, including drug-resistant organisms. J Gastroenterol Hepatol. 2002; 17: 482 - 7.
15. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. The antibacterial action of bismuth in relation to Campylobacter pyloridis colonisation and gastritis. Digestion. 1987; 37 (Suppl 2): 16 - 30.
16. Bayerdoffer E, Mannes GA, Sommer A. High dose omeprazole treatment combined with amoxicillin eradicates H. pylori. Eur J Gastroenterol Hepatol. 1992; 4: 697 - 702.
17. Kashifard M, Malekzadeh R, Siavoshi F, Mikaeli J, Massarrat S. Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin. Eur J Gastroenterol Hepatol. 1998; 10: 847 - 50.
18. Bazzoli F, Zargari RM, Fossi Spozzato P, Rida A, Roda E. Efficacy and tolerability of a short term, low-dose triple therapy for the eradication of H. pylori. Gastroenterology. 1993; 104: A14 0.
19. Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, Misiuna P, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in atients with gastric ulcer. Aliment Pharmacol Ther. 1999; 13: 703 - 12.
20. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999; 116: 248 - 53.
21. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther. 1999; 13: 289 - 95.
22. Saberi-Firoozi M, Massarrat S, Zare S, Fattahi M, Javan A, Etaati H, et al. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol. 1995; 90: 1419 - 23.
23. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19: 89 - 93.
24. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003; 18: 778 - 82.
25. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003; 17: 1137-43.
26. de Boer WA, Driessen WM, Jansz AR, Tytgat GN. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepatol. 1995; 7: 1189 - 94.
27. Mikaeli J, Mir-Nasseri MM, Manafi-Anari A. Evaluation of OAMB quadraple therapy for Helicobacter pylori eradication in patients with peptic ulcer disease and gastroduodenitis [in Persian]. Govaresh; 2004 [in press].
28. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15: 411 - 6.
29. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther. 2000; 14: 299 - 303.
30. Charles Lacy. Furazolidone: drug information. UpToDate. Version 11.2.
31. Dal Bo' N, Di Mario F, Battaglia G, Buda A, Leandro G, Vianello F, et al. Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? J Gastroenterol Hepatol. 1998; 13: 288 - 93.
32. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996; 10: 1029 - 33.
33. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin, and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14: 603 - 9.
34. Peura DA. Treatment regimens for Helicobacter pylori.
35. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol. 2003; 18: 13 - 7.
36. Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, et al. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth subcitrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol. 2001; 13: 915 - 9.
37. Megraud F, Burette A, Glupczynski Y, Fiocca R, Logan R, Quina M, et al. Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. Eur J Gastroenterol Hepatol. 2000; 12: 629 - 33.
38. Vaira D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Gasbarrini G, et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol. 2000; 95: 925 - 9.
39. Lee JM, Deasy E, O'Morain CA. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol. 2000; 12: 433 - 7.
40. Fallone CA, Loo V, Joseph L, Barkun J, Kostyk R, Barkun AN. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer resurgence: a randomized controlled trial. Clin Invest Med. 1999; 22: 185 - 94.
41. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002; 16 (Suppl 1): 24 - 30.
42. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci. 2000; 45: 265 - 71.
43. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999; 159: 2312 - 6.
44. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17: 1333 - 43.
45. Megraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. J Clin Gastroenterol. 1995; 20 (Suppl 1): S24 - 7.
46. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002; 16: 1047 - 57.
47. Ali' A, Menegatti M, Gatta L, Landi F, Ricci C, Acciardi C, et al. A second line anti-Helicobacter pylori therapy in patients with previously failed treatment. Am J Gastroenterol. 1999; 94: 2321 - 3.
48. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999; 13: 1047 - 55.
49. Megraud F, Lehn N, Lind T, Bayerdorffer E, O'Morain C, Spiller R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH2 study. Antimicrob Agents Chemother. 1999; 43: 2747 - 52.
50. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, Kwon DH, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000; 14: 745 - 50.
51. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second line Helicobacter pylori eradication with a farazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion. 2001; 64: 222 - 5.
52. Sicilia B, Sierra E, Lago A, Villar M, Garcia S, Gomollon F. High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy. Med Clin (Barc). 2000; 115: 641 - 3.
53. Magaret N, Burm M, Faigel D, Kelly C, Peterson W, Fennerty MB. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis. 2001; 19: 174 - 8.
54. O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003; 17: 415 - 20.
55. Hilderbrand P, Bardhan P, Rossi L, Parvin S, Rahman A, Arefin MS, et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology. 2001; 121: 792 - 8.
56. van der Hulst RWM, Koycu B, Keller JJ. H. pylori reinfection after successful eradication analyzed by RAPD or RFLP. Gastroenterology. 1996; 110: A284.
57. Ahuja V, Sharma MP. High recurrence rate of Helicobacter pylori infection in developing countries. Gastroenterology. 2002; 123: 653 - 4.
58. Zahedi MJ, Malekzadeh R, Saghari M, Sajjadi A, Khatibian M, Ansari R. Annual reinfection rate with H. pylori positive acid-peptic disease in Iranian patients after eradication. Gastroenterology. 1997; 112: A207.
59. Siavoshi F, Salmanian AH, Rofougaran R, Malekzadeh R, Massarrat S. Yeasts of the oral cavity are the reservoirs of Helicobacter pylori (HP). Govaresh. 2003; 42: 204.
60. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter. 2003; 8: 95 -104.